# ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

> **NCT06194799** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 752 (estimated)

## Conditions studied

- Alzheimer's Disease Psychosis

## Interventions

- **DRUG:** ACP-204

## Key facts

- **NCT ID:** NCT06194799
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-04-23
- **Primary completion:** 2029-04
- **Final completion:** 2029-05
- **Target enrollment:** 752 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06194799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06194799, "ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06194799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*